Two different potential biomarkers for amyotrophic lateral sclerosis (ALS) have been identified, which it's hoped will help stratify patients and guide clinical trials of new therapies. One biomarker ...

SALT LAKE CITY, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late ...

The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are ...

NEW YORK, May 6, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced its participation in the 4th ...

QurAlis intends to advance QRL-101 into proof-of-concept studies as a potentially best-in-class treatment for both ALS and epilepsy CAMBRIDGE, Mass., March 12, 2025 /PRNewswire/ -- QurAlis Corporation ...

The discovery holds promise to provide drug developers with an objective measure for clinical trials, help identify new pathways, and enable earlier identification LinusBio, a leader in exposomic ...

Clene (NASDAQ:CLNN) executives told investors the clinical-stage biopharmaceutical company has secured an in-person meeting with the U.S. Food and Drug Administration (FDA) later this quarter as it co ...

CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023) 60% decreased risk of ...

Tania Gendron, PhD, speaks to the present challenges for translating biomarker discoveries to clinical practice and offers insights to how these can be overcome. Biomarker exploration has been a ...

FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 Biomarker improvements are strongly associated with longer survival, ...